What Is Myelodysplastic Syndrome?

Slides:



Advertisements
Similar presentations
Current Treatment Options in MDS Dick Wells MD, DPhil, FRCPC Director, Crashley Myelodysplastic Syndrome Research Laboratory Odette Cancer Centre.
Advertisements

MDS - Diagnosis and Treatments
Clinical importance and safety of ESAs for patients with Myelodysplastic Syndromes (MDS) Steven D. Gore, MD Associate Professor of Oncology Sidney Kimmel.
CB-1 MDS Classification and Prognosis John M. Bennett, MD University of Rochester Medical Center Hematomorphologist Chair, MDS Foundation.
ANCO 2006 ASH UPDATE MDS Joseph M. Tuscano, M.D. UC Davis Cancer Center.
1 Oliva EN et al Proc ASH 2015;Abstract 91.
Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12
Myelodysplastic Syndromes
Myelodysplastic syndrome(MDS)
The Patient Experience With Systemic Lupus Erythematosus
The Nurse View: Management of Pancreatic Cancer
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
IBD Therapies: Guidance for Managed Care Professionals
NOACs for Cancer-Associated Thrombosis:
Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Perspectives on Triple-Negative Breast Cancer
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Program Goals Case 1: Woman With MDS Risk: Cytogenetic Subgroups.
Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome
The Comprehensive Major Depressive Disorder Care Team
Kantarjian H et al. Cancer 2009;[Epub ahead of print].
Update on Clostridium difficile Infection
Fenaux P et al. Lancet Oncol 2009;10(3):
Bone Biology and Osteoporosis: Back to the Basics
Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.
Current and Future Goals in the Treatment of Relapsed CLL
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower- Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005.
Treating Transplant-Ineligible Patients With Multiple Myeloma
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Treatment of Generalized Tonic-Clonic Seizures in the Modern Era
Myelodysplastic Syndromes
The Nurse View: Best Practices in Multiple Myeloma
How Can we Improve Outcomes for the Elderly Patient with AML?
MDS: Introduction. Supportive Care in the Treatment of Lower-Risk Myelodysplastic Syndromes.
Team-Based Perspectives on Successful Approaches in Treating Obesity
Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant 
Improving Therapeutic Management of Huntington's Disease in Long-Term Care.
Impactful Data in TD That Can Guide Treatment Decisions
Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.
Advancing the Treatment of IBD With Biologics
When Is Biologic Therapy Appropriate for HS?
Bone Biology and Osteoporosis: Back to the Basics
Myeloid Updates From the Summer Congresses
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
MYELODYSPLASTIC SYNDROME: prognosis & treatment options
Implications of Emerging Treatments for Beta-Thalassemia
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
New ELN Recommendations
Expert Perspectives in the Recognition and Management of Lennox-Gastaut Syndrome.
Bone Biology and Osteoporosis: Back to the Basics
Managing Anemia in Lower-Risk MDS
Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive.
Biology of Blood and Marrow Transplantation
Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.
Improving Overall Health
Improving Adherence to Antiplatelet Therapy After an ACS Event
Treating Atypical Hemolytic Uremic Syndrome A Case Discussion
Perspective on the Multidisciplinary Management of PAH
Renal Function and Myeloma Therapeutics
Addressing Cardiovascular Events:
PAH Pathways: What Do the Data Tell Us?”
ASH Review 2018: Update on Myelodysplastic Syndrome
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse:
Expert Perspectives.
Ask the Psoriasis Expert
Risk Stratification in MDS
Algorithm for treatment choice in MDS patients after failure of HMA therapy. Algorithm for treatment choice in MDS patients after failure of HMA therapy.
Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment.
Presentation transcript:

Approach to Management of Myelodysplastic Syndromes: A Nursing Perspective

What Is Myelodysplastic Syndrome?

How Common Is MDS?

Staging of MDS With IPSS

Staging of MDS With IPSS (cont)

Treatment Objectives for MDS

When Do You Treat Lower-Risk MDS?

Supportive Care: Transfusions

Erythroid-Stimulating Agents

ESA Nursing Implications

Lenalidomide in Lower-Risk MDS

Nursing Implications for Lenalidomide

Nursing Implications for Lenalidomide

Therapeutic Options for Higher-Risk MDS

Hypomethylating Agents

Nursing Implication in HMAs

Nursing Implications for Allogeneic Transplant

Physical Factors for Treatment Decisions

Psychosocial Factors Influencing Treatment

Nurse Responsibility in Shared Decision Making

Abbreviations

References

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.